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Long QT Syndrome
Ilan Goldenberg, MD, Arthur J. Moss, MD
Rochester, New York
The hereditary long QT syndrome (LQTS) is a genetic channelopathy with variable penetrance that is associated
with increased propensity to syncope, polymorphous ventricular tachycardia (torsades de pointes), and sudden
arrhythmic death. This inherited cardiac disorder constitutes an important cause of malignant ventricular ar-
rhythmias and sudden cardiac death in young individuals with normal cardiac morphology. Risk assessment in
affected LQTS patients relies upon a constellation of electrocardiographic, clinical, and genetic factors. Adminis-
tration of beta-blockers is the mainstay therapy in affected patients, and primary prevention with an implantable
cardioverter defibrillator or left cervicothoracic sympathetic denervation are therapeutic options in patients who
remain symptomatic despite beta-blocker therapy. Accumulating data from the International LQTS Registry have
recently facilitated a comprehensive analysis of risk factors for aborted cardiac arrest or sudden cardiac death in
pre-specified age groups, including the childhood, adolescence, adulthood, and post-40 periods. These analyses
have consistently indicated that the phenotypic expression of LQTS is time dependent and age specific, warrant-
ing continuous risk assessment in affected patients. Furthermore, the biophysical function, type, and location of
the ion-channel mutation are currently emerging as important determinants of outcome in genotyped patients.
These new data may be used to improve risk stratification and for the development of gene-specific therapies
that may reduce the risk of life-threatening cardiac events in patients with this inherited cardiac disorder.
(J Am Coll Cardiol 2008;51:2291–300) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.068w
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ihis review focuses on the inherited form of the long QT
yndrome (LQTS) and will not cover acquired causes of QT
rolongation. Hereditary LQTS is a familial disorder in
hich most affected family members have delayed ventric-
lar repolarization as manifest on the electrocardiogram
ECG) as QT prolongation. This genetic channelopathy
as variable penetrance, with affected individuals having an
ncreased propensity to syncope, polymorphous ventricular
achycardia (torsades de pointes), and sudden arrhythmic
eath. The estimated overt prevalence of this disorder is in
he range of about 1:5,000 subjects. However, because the
umber of genotyped LQTS patients having 2 LQTS
utations is approximately 10%, the prevalence of LQTS
atients with overt or subclinical disorders is likely to be
onsiderably greater than the currently estimated prevalence.
The first family with LQTS, described by Jervell and
ange-Nielsen in 1957, consisted of 4 children with deaf-
ess, recurrent syncope, sudden cardiac death, and QT
rolongation on the ECG (1). Subsequently, this disorder
as found to be due to homozygous mutations of the
CNQ1 gene, with the deafness being a recessive manifes-
ation of the reduced potassium current (IKr). Romano et al.
n 1963 (2) and Ward in 1964 (3) described families in
rom the Cardiology Division, Department of Medicine, University of Rochester
edical Center, Rochester, New York. Drs. Goldenberg and Moss contributed
qually to this paper.c
Manuscript received December 31, 2007; revised manuscript received February 19,
008, accepted February 26, 2008.hich affected members had QT prolongation, recurrent
yncope, and sudden death without deafness with an auto-
omal dominance pattern of inheritance. The first therapy
or this disorder was reported in 1971 with the introduction
f left cervicothoracic sympathetic denervation (LCSD) (4).
he usefulness of beta-blockers in the treatment of this
isorder was appreciated in the mid-1970s. The Interna-
ional Long QT Syndrome Registry was established in
979, and extensive clinical and genetic studies have been
nd are derived from this Registry (5). The Registry
urrently involves 1,276 proband-identified LQTS families
nvolving over 3,600 clinically or borderline affected family
embers with about 2,000 of these family members with
enetically confirmed LQTS mutations. Publications from
he International LQTS Registry have provided insight into
isk mechanisms; genotype-phenotype associations; risk
tratification by age, gender, and genotype; and the impor-
ance of syncope as a cardiac event that frequently precedes
borted cardiac arrest (ACA) or sudden cardiac death
SCD).
enetic and Molecular Understanding
linically, LQTS is identified by abnormal QT interval pro-
ongation on the ECG. The QT prolongation may arise from
ither a decrease in repolarizing potassium currents or an
nappropriate late entry of sodium into the myocyte (6). Most
ommonly, QT prolongation is produced by delayed repolar-
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Long QT Syndrome June 17, 2008:2291–300ization due to mutations in the
-subunit of ion channels involv-
ing either the slowly (IKs, KCNQ1,
LQT1) or rapidly (IKr, KCNH2,
LQT2) acting repolarizing cardiac
potassium currents (7). Infrequent
forms of LQTS may result from
mutations involving the auxiliary
-subunits to KCNQ1 (minK,
LQT5) (8) and KCNH2 (MiRP1,
LQT6) (9), although there is not
full agreement regarding the func-
tion of MiRP1. Mutations of the
sodium-channel protein are associ-
ated with prolonged depolarization
due to a small persistent inward
leak” in cardiac sodium (Na) current INa (SCN5A, LQT3)
10). TheLQT1, LQT2, LQT3, LQT5, andLQT6 genesmake
p the classic genetic forms of LQTS. At the present time,
ver 300 different LQTS-related mutations have been
dentified on these 5 genes (11), and it is this group of
on-channel genes that has characterized LQTS as a
hannelopathy. During the past few years, mutations in
ther genes have been identified in single individuals or
ust a few families in what can be categorized as “LQTS-
elated” disorders. These disorders involve mutations in
he following genes: ankyrin-B gene, which functions as
cytoskeletal membrane adapter (LQT4) (12); KCNJ2
ene, with reduction in Kir2.1 current and a phenotype
ominated by skeletal abnormalities (Andersen-Tawil
yndrome) (LQT7) (13); CACNA1C gene, with increase
n Cav1.2 current and associated with syndactyly in both
ands and feet (Timothy syndrome) (LQT8) (14);
avelolin-3 gene, with increase in late sodium current
LQT9) (15); and SCN4B gene, also with increase in late
odium current (LQT10) (16). Whether these genes
Abbreviations
and Acronyms
ACA  aborted cardiac
arrest
ECG  electrocardiogram
ICD  implantable
cardioverter-defibrillator
LCSD  left
cervicothoracic
sympathetic denervation
LQTS  long QT syndrome
QTc  corrected QT
SCD  sudden cardiac
death
Figure 1 Distinctive T-Wave Patterns in the 3 Major LQTS Geno
T-wave morphology by LQTS genotype: LQT1: typical broad-based T-wave pattern (c
T-wave (QTc 583 ms); and LQT3: typical late-onset peaked/biphasic T-wave (QTc 5hould be categorized as LQTS4, LQTS7, LQTS8,
QTS9, and LQTS10 genotypes, respectively, is some-
hat controversial at this time.
The protein structure of each of the ion channels
KCNQ1, KCNH2, SCN5A) consists of a series of aminio
cids with an N-terminus region, the 6 membrane-spanning
egments with connecting intracellular cytoplamic loops
S2–S3 and S4–S5) and a pore area (S5–S6), and a
-terminus region. The KCNQ1 (LQT1) and KCNH2
LQT2) genes belong to the family of voltage-gated potas-
ium ion channels in which a tetramer of 4 -subunits
akes up each channel. The SCN5A sodium channel is a
ingle protein, a conjoined tetramer with 4 -subunit
ivisions. Two distinct biophysical mechanisms mediate the
educed repolarizing current in patients with potassium-
hannel mutations: 1) coassembly or trafficking defects, in
hich mutant subunits are not transported properly to the
ell membrane and fail to incorporate into the tetrameric
hannel, with the net effect being a 50% reduction in
hannel function (haploinsufficiency); and 2) formation of
efective channels involving mutant subunits, with the
ltered channel protein transported to the cell membrane
nd resulting in a dysfunctional channel having 50%
eduction in channel current (dominant-negative effect). In
atients with SCN5A sodium-channel mutations, the chan-
el fails to close properly after initial depolarization and
ontinued leakage of sodium into the channel results in
rolongation of the action potential.
Genotype-phenotype studies of LQTS have provided
ew insights into risk mechanisms, electrocardiographic
eatures, and long-term clinical course associated with
his inherited disorder. For example, each of the 3 major
enotypes (LQT1 to LQT3) seems to have a distinctive
-wave repolarization pattern on the ECG, as shown in
igure 1 (17,18).
s
d QT [QTc] 570 ms); LQT2: typical bifid
). Reprinted, with permission, from Moss et al. (17).type
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June 17, 2008:2291–300 Long QT Syndromeiagnosis
he diagnosis of LQTS relies mainly on ECG findings and
linical history. When marked corrected QT (QTc) prolon-
ation is present, the diagnosis is straightforward. For less
lear cases, a scoring system has been introduced in which
ther characteristics are taken into account.
CG assessment. An accurate measurement of the QT
nterval is valuable for the diagnosis of LQTS. The QT
nterval should be determined as a mean value derived from
t least 3 to 5 cardiac cycles (heart beats), and is measured
rom the beginning of the earliest onset of the QRS
omplex to the end of the T-wave. The QT measurement
hould be made in leads II and V5 or V6, with the longest
alue being used. The QT interval is usually corrected for
eart rate using the Bazett formula (QTc  QT/RR0.5,
ith all intervals in seconds) which remains the standard for
linical use despite some limitations at particularly fast or
low heart rates (in which the formula may overcorrect or
ndercorrect, respectively). Based on analysis of digitized
ata for QT and RR interval measurements in healthy
ndividuals, a simple 3-level ECG classification was devel-
ped (Table 1) (19).
linical assessment. When a prolonged QTc is identified
fter a syncopal event in the absence of acquired causes of
T prolongation (see subsequent text) the diagnosis of
QTS can be made, and ECGs should be obtained on all
rst-degree family members to determine whether others
re affected. Unexplained sudden death in a young individ-
al should trigger a similar evaluation to determine if LQTS
s present in the family. Rarely, an asymptomatic individual
s identified with LQTS by QTc prolongation on an ECG
btained for another reason.
Gathering detailed information regarding family history
n a suspected individual is essential because careful ques-
ioning may reveal a long-term pattern of similar episodes
syncope, sudden death), not only in first-degree relatives
mother, father, siblings, children), but also in more remote
elatives in the family. Data on comorbidities in evaluated
ndividuals or family members (such as congenital deafness)
hould also be acquired.
It is important to distinguish acquired factors that result
n QT prolongation from the inherited form of LQTS
hrough careful history. Causes of abnormal prolongation of
he QT interval include myocardial ischemia, cardiomyop-
thies, hypokalemia, hypocalcemia, hypomagnesemia, auto-
omic influences, drug effects, and hypothermia.
uggested Bazett-Corrected QTcalues for Di gnosing QT Prolongation
Table 1 Suggested Bazett-Corrected QTcValues for Diagnosing QT Prolongation
Rating 1–15 yrs Adult Male Adult Female
Normal 440 430 450
Borderline 440–460 430–450 450–470
Prolonged 460 450 470ialues are given in ms. Reprinted, with permission, from Goldenberg et al. (19).When the diagnosis is not clear, a clinical scoring system
ased on personal and family history, symptomatology, and
CG has been developed (Table 2) (20). Additional meth-
ds of testing, including Holter and exercise testing, have
een suggested to improve diagnosis in borderline cases.
olter monitoring is not sufficiently well standardized to
erve in the primary assessment for ventricular repolariza-
ion analysis. However, this method can sometimes be used
or the detection of extreme QT interval events that occur
nfrequently during the day (21). Exercise testing, with a
tandard activity protocol, can be used for the evaluation of
T prolongation during the exercise and recovery periods
22). However, the adaptation of QT interval duration to
eart rate is not instantaneous, and substantial errors may be
ntroduced if nonstationary episodes are analyzed. A differ-
ntial response of LQT1 and LQT2 patients to epinephrine
nfusion has been reported, and epinephrine challenge was
uggested to be a significant provocative test in the unmask-
ng of low-penetrance KCNQ1 mutation carriers (23).
ole of genetic testing. Genetic testing has so far largely
een used for research purposes, making the phenotypic
ssessment cited in the preceding text the mainstay in the
iagnosis of this genetic disorder. The recent commercial
arketing of short-turnaround-time (approximately 6
eeks) LQTS genetic diagnostic testing, and increasing
vailability of testing through university-affiliated laborato-
ies, may establish genetic testing as a clinical tool. How-
ver, before widespread use, the clinical validity of LQTS
enetic testing needs to be more widely established. In a
ecent study of 541 consecutive unrelated patients referred
o the Mayo Clinic’s Sudden Death Genomics Laboratory
or LQTS genetic testing (24), the yield of genetic testing
as shown to be highest (72%) among tested individuals
ith the highest clinical probability. Thus, the current
enetic test can be expected to capture approximately
hree-fourths of phenotypically affected LQTS individuals,
hereas a negative genetic test in a subject with clinical
QTS (i.e., genotype-negative/phenotype-positive LQTS)
rovides no basis for removing the diagnosis (25). Despite
his, a positive genetic test may influence treatment deci-
ions (see subsequent text) and may provide the means for
recise “carrier” status classification of potentially at-risk
elatives. Furthermore, genetic testing may be important in
he identification of concealed LQTS, because a significant
inority (25% to 50%) of individuals with genetically
roven LQTS have a nondiagnostic QTc (26).
linical Course
he clinical course of patients with LQTS is variable, owing
o incomplete penetrance. It is influenced by age, genotype,
ender, environmental factors, therapy, and possibly other
odifier genes (27–29). Importantly, the clinical risk in
QTS is age specific. Therefore, continuous risk assessment
s warranted in patients with this genetic disorder. The main
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Long QT Syndrome June 17, 2008:2291–300linical and genetic risk factors in LQTS are considered
eparately in the following sections.
ender. Accumulating data from the International LQTS
egistry demonstrate that the phenotypic expression of LQTS
isplays major time-dependent gender differences in the risk of
onfatal and life-threatening cardiac events (Fig. 2) (30).
ocati et al. (31) showed that male gender is independently
ssociated with a significant 85% and 72% increase among
robands and affected family members, respectively, in the risk
f cardiac events (comprising syncope, ACA, or SCD) before
ge 15 years, whereas a gender risk reversal was shown to occur
fter age 14 years, in which girls displayed an 87% increase in
he risk of cardiac events compared with boys among probands
nd a 3.3-fold increase in the risk among affected family
embers. Zareba et al. (32) showed that during childhood,
QT1 boys exhibited a 71% increase in the risk of a first
ardiac event compared with corresponding girls, whereas no
ignificant gender-related difference in the risk was shown
mong LQT2 and LQT3 carriers during the same time
eriod. Consistent with the results of Locati et al. (31), that
tudy demonstrated gender risk reversal after age 16 years, in
hich the risk of cardiac events was more than 3-fold higher
mong both LQT1 and LQT2 girls compared with the
espective boys.
More recent studies from the International LQTS Reg-
stry, in which risk factors for life-threatening cardiac events
ACA or SCD) were assessed (28,29,33), demonstrated that
he onset of gender risk reversal for this more severe end
oint occurs at a later age (Fig 2B). In a study of 3,015
iagnostic Criteria for LQTS
Table 2 Diagnostic Criteria for LQTS
Finding Score
Electrocardiographic†
Corrected QT interval, ms
480 3
460–470 2
450 (in males) 1
Torsades de pointes‡ 2
T-wave alternans 1
Notched T-wave in 3 leads 1
Low heart rate for age§ 0.5
Clinical history
Syncope‡
With stress 2
Without stress 1
Congenital deafness 0.5
Family history
Family members with definite LQTS 1
Unexplained SCD in immediate family members 30 yrs old 0.5
coring: 1 point, low probability of long QT syndrome (LQTS); 2 to 3 points, intermediate
robability of LQTS; and 4 points, high probability of LQTS. †Findings in the absence of
edications or disorders known to affect these electrocardiographic findings. The corrected QT
nterval is calculated by Bazett’s formula: QT/RR0.5. ‡Torsades de pointes and syncope are
utually exclusive. §Resting heart rate below the second percentile for age. The same family
ember cannot be counted in both categories. Reprinted, with permission, from Schwartz
t al. (20).
SCD  sudden cardiac death.QTS children, the cumulative probability of a first life-hreatening cardiac event from age 1 to 12 years was 5% in
oys compared with only 1% among girls (p  0.001) (33),
hereas in the age range of 12 to 20 years, Hobbs et al. (28)
howed that there is no significant gender difference in the
isk. Risk reversal for the end point of ACA or SCD was
hown to occur after the age of 20 years. Sauer et al. (29), in
n analysis of 812 mutation-confirmed LQTS patients,
howed that during adulthood, women have nearly a 3-fold
ncrease in the risk of ACA or SCD compared with men.
he risk associated with female gender in the post-
dolescence period may be related to hormonal factors.
ndrogens were shown to blunt QT-interval prolongation
n response to quinidine (34) and therefore may be associ-
ted with QT shortening in men after childhood. In
ontrast, estrogens were demonstrated to modify the expres-
ion of potassium channels and may have a dose-dependent
locking effect on IKs (35). The possible relationship be-
ween female hormones and arrhythmic risk is also sup-
orted by a recent study from the Registry that showed a
ignificant increase in the risk of cardiac events in the
-month post-partum period, mainly among women who
ere identified as LQT2 genotype carriers (36).
Figure 2 Probability of LQTS-Related Events by Gender
Kaplan-Meier estimates of the cumulative probability of (A) a first cardiac
event (syncope, aborted cardiac arrest [ACA], or sudden cardiac death [SCD])
and (B) a first life-threatening cardiac event (ACA or SCD) from age 1 through
75 years by gender in 3,779 long QT syndrome (LQTS) patients from the Inter-
national LQTS Registry. Reprinted, with permission, from Goldenberg et al. (30).
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June 17, 2008:2291–300 Long QT SyndromeTc duration. A baseline QTc interval of 500 ms has
onsistently been shown to be associated with a high risk of
ardiac events (comprising syncope ACA or SCD) in LQTS
atients (37–41). More recent data regarding risk factors for
ife-threatening cardiac events (ACA or SCD) have confirmed
he role of baseline QTc duration as a major risk factor for this
nd point (28,29,33). In the study by Hobbs et al. in LQTS
dolescents (age 28), a baseline QTc duration of530 ms was
hown to be independently associated with a 2.3-fold (p 
.001) increase in the risk of ACA or SCD compared with
horter QTc values. Consistently, Sauer et al. (29) demon-
trated that in LQTS adults, baseline QTc durations between
00 and 549 ms were associated with a 3.3-fold increase in the
isk of ACA or SCD compared with shorter QTc values, and
Tc 550 ms was associated with a 6.3-fold increase in the
isk. These studies, however, assessed only the risk associated
ith QTc duration that was measured at the baseline, first
ecorded ECG. We have recently shown that follow-up
CG recordings provide important incremental prognostic
nformation in LQTS patients (42). In a study of 375
hildren with ECG follow-up data, we showed that there is
onsiderable variability in QTc interval duration when serial
CGs are recorded, and that the maximum QTc duration
easured at any time during follow-up is the most powerful
redictor of subsequent cardiac events, regardless of baseline
Tc values (42). These findings further demonstrate that
he phenotypic expression of LQTS is dynamic and suggest
hat QTc data from follow-up ECG recordings should be
ncorporated into the risk assessment of LQTS patients.
Age-Specific Risk Factors for Life-Threatening C
Table 3 Age-Specific Risk Factors for Life-Th
Age Group (Ref. #) Risk Facto
Childhood (1–12 yrs) (33) Male gender
QTc 500 ms
Prior syncope
Recent (2 yrs)
Remote (2 yrs)
Adolescence (10–20 yrs) (28) QTc 530 ms
Syncope
2 syncopal events in
1 syncopal event in pa
2 syncopal events in
1 syncopal events in p
Adulthood (18–40 yrs) (29) Female gender
QTc duration
QTc 500 ms
QTc 500–549 ms
Prior syncope
Adulthood (41–60 yrs) (53)† Recent syncope (2 yrs)
QTc 530 ms
LQT3 genotype
*Findings are from separate multivariable Cox models in each age g
†Because long QT syndrome (LQTS)–related events are more difficult
group comprised aborted cardiac arrest or death from any cause. ‡Lac
to the broad end point of death from any cause.
QTc  corrected QT interval.ime-dependent syncope. Early LQTS studies have tradi-
ionally assessed the combined end point of a first cardiac event
comprising syncope, ACA, or LQTS-related SCD). In these
tudies, the predominant component in the combined end
oint was syncope, mainly owing to sample size limitations.
ecent data from the International LQTS Registry have
acilitated a comprehensive analysis of risk factors for the more
evere end point of ACA or SCD that is clinically more
mportant in the affected population (28,29,33). These studies
ave consistently demonstrated that a history of syncope,
ssessed as a time-dependent factor, is the most powerful
redictor of subsequent life-threatening cardiac events in
QTS patients. Furthermore, the timing and frequency of the
yncopal events were also shown to affect outcome. Thus, in
QTS adolescents (age 10 to 20 years), patients with 2 or more
yncopal episodes in the last 2 years were shown to have an
8-fold increase in the risk of subsequent life-threatening
ardiac events (p  0.001), those with 1 syncopal episode in
he last 2 years had a 12-fold increase in the risk (p  0.001),
nd those with 1 or 2 or more episodes of syncope 2 to 10 years
efore (but none in the last 2 years) had a 3-fold increase in the
isk compared with patients without a history of syncope in the
ast 10 years (Table 3) (28). Similarly, in LQTS adults (age 18
o 40 years) time-dependent syncope after age 18 years was
hown to be associated with 5-fold increase in the risk of
ubsequent life-threatening cardiac events, whereas more dis-
ant syncopal history (before age 18 years) was not a significant
isk factor (29). These findings further stress the importance of
ynamic risk assessment in LQTS patients.
c Events in LQTS Patients*
ening Cardiac Events in LQTS Patients*
Hazard Ratio
(p Value)
Beta-Blocker Efficacy,
% Reduction (p Value)
3.96 (0.001) 73% (0.002)
2.12 (0.02)
14.34 (0.001)
6.45 (0.001)
2.3 (0.001) 64% (0.01)
yrs 18.1 (0.001)
s 11.7 (0.001)
–10 yrs 5.8 (0.001)
10 yrs 2.7 (0.001)
2.68 (0.05) 60% (0.01)
6.35 (0.01)
3.34 (0.01)
5.10 (0.01)
9.92 (0.001) 42% (0.40)‡
1.68 (0.06)
4.76 (0.02)
r the end point of aborted cardiac arrest or sudden cardiac death.
eate in the older age group, the end point in the 41 to 60 years age
tatistically significant beta-blocker effect in this age group may relateardia
reat
r
past 2
st 2 yr
past 2
ast 2–
roup fo
to delin
k of a s
L
s
(
o
h
g
s
w
L
t
a
e
(
s
t
L
r
s
L
m
w
L
r
s
L
o
i
(
a
m
s
r
i
B
c
L
i
o
c
6
p
d
d
w
P
a
t
(
a
C
N
d
w
e
m
a
m
e
s
q
r
U
c
t
e
2296 Goldenberg and Moss JACC Vol. 51, No. 24, 2008
Long QT Syndrome June 17, 2008:2291–300QTS genotypes. Gene-specific differences have been de-
cribed in terms of morphology of the ST–T wave complex
Fig. 1) (17,18), triggers for cardiac events (43–45), and risk
f cardiac events (38–40). Life-threatening cardiac events
ave been shown to occur under specific circumstances in a
ene-specific manner. Patients with the LQT1 genotype
eem to have a high frequency of cardiac events associated
ith vigorous physical activities, whereas patients with the
QT2 genotype are at high risk of having arrhythmic events
riggered by a sudden loud noise, such as the ringing of an
larm clock. Patients with the LQT3 genotype experience
vents without emotional arousal during sleep or at rest
43–45). Swimming has been described as an LQT1-
pecific arrhythmogenic trigger (45). It has been suggested
hat arrhythmic risk is related to the presence of specific
QTS genotypes. A previous study, which assessed the
isk of cardiac events of any type, demonstrated a
ignificantly higher risk among patients with LQT1 and
QT2 mutations compared with those with LQT3
utations (39). However, the lethality of cardiac events
as found to be significantly higher in LQT3 than in
QT2 and LQT1 family members (39). More recent
eports that assessed the end point of ACA or SCD
uggest that data regarding a specific genotype (LQT1,
QT2, or LQT3) do not contribute significantly to
utcome after adjustment for clinical risk factors, includ-
ng gender, QTc duration, and time-dependent syncope
28,29,33). This may be related to variable penetrance
mong patients carrying the same genotype (46). Several
odifier factors, including genetic polymorphisms in the
ame gene carrying the primary genetic defect and envi-
onmental factors have been implicated as determinant of
ncomplete penetrance (27).
iophysical function and location of LQTS mutations. Re-
ent genotype-phenotype studies from the International
QTS Registry have provided important information regard-
ng the effect of location, coding type, and biophysical function
f the channel mutations on the phenotypic manifestations and
linical course of LQTS patients (Fig. 3) (47,48). In a study of
00 patients with 77 different KCNQ1 mutations, the bio-
hysical function of the mutations, categorized according to
ominant-negative (50%) or haploinsufficiency (50%) re-
uction in cardiac repolarizing IKs potassium channel current,
as shown to be an important determinant of outcome.
atients with dominant-negative ion channel dysfunction had
2-fold increase in the risk of cardiac events compared with
hose who harbored mutations with haploinsufficiency effects
p  0.001), and patients with transmembrane mutations had
significantly higher risk of cardiac events compared with
-terminus mutations (hazard ratio 2.06; p  0.001) (47).
otably, several recent studies have reported that the
ominant-negative KCNQ1-A341V mutation is associated
ith a particularly high clinical severity independently of the
thnic origin of the families (49–51). The location of the
utation was also shown to be an important determinant of
rrhythmic risk in LQT2 patients (48). Patients with pore putations in the LQT2 gene were shown to have more severe
lectrocardiographic and clinical manifestations compared with
ubjects with nonpore mutations, resulting in a higher fre-
uency of arrhythmia-related cardiac events (74% vs. 35%,
espectively; p  0.001) occurring at an earlier age (48). The
.S., Japan, and the Netherlands LQTS registries are currently
ooperating in the analysis of the risk associated with addi-
ional mutation sites in LQT2 patients and of the phenotypic
xpression of different ion-channel mutations in LQT3
Figure 3 Probability of Cardiac Events in LQT1 Patients
Kaplan-Meier estimates of the cumulative probability of a first cardiac
event in KCNQ1 mutation carriers (LQT1 genotype) by (A) location,
(B) type, and (C) biophysical function of the mutation. Reprinted, with
permission, from Moss et al. (47).atients.
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June 17, 2008:2291–300 Long QT Syndromeisk stratification for life-threatening cardiac events in
QTS patients. Based on published mortality rates, LQTS
isk groups may be categorized as high (history of aborted
ardiac arrest and/or ECG-documented episodes of torsades
e pointes), intermediate (time-dependent syncopal history
nd/or QTc prolongation 0.50 s), and low (affected subjects
ithout history of prior syncope and with QTc duration0.50
) risk (Fig. 4) (52). It should be remembered, however, that
hese risk groups represent a simplified approach, because risk
actors in LQTS are time dependent and age specific. More
pecific data from recent Registry studies regarding high-risk
ubsets for life-threatening cardiac events in each age group are
resented in Table 3 (28,29,33,53).
herapeutic Consideration
wing to the low prevalence of LQTS, it is not possible to
ssess the benefit of suggested therapies through prospective
andomized trials. Therefore, data regarding therapeutic effi-
acy in affected patients are based on observational long-term
tudies in heterogeneous risk subsets, necessitating complex
tatistical analyses to avoid possible bias related to nonran-
omized administration of proposed LQTS-related thera-
ies to high-risk patients. Medical, device, and surgical
herapies have been evaluated for the primary and secondary
revention of LQTS-related cardiac events. These are
onsidered separately in the following sections.
eta-blockers. Medical therapy with beta-blockers is con-
idered to be first-line prophylactic therapy. These drugs
hould be administered to all intermediate- or high-risk
ffected individuals and considered on an individual basis in
ow-risk patients (Fig. 4). An alternative therapeutic ap-
roach, recommended by some physician-investigators, is to
dminister beta-blockers in all LQTS patients, even those at
Figure 4 Suggested Risk-Stratification Scheme for ACA or SCD
Risk stratification categories for LQTS patients based on published event rates; m
estimates are based on a series of 869 LQTS patients (52). CPR  cardiopulmonery low risk, unless there is a contraindication. Their
echanism of action is probably related to the attenuation
f adrenergic-mediated triggers in this disorder, especially
n individuals with the LQT1 and LQT2 genotypes (43). In
study of 139 genotyped patients, beta-blocker therapy was
ssociated with a significant reduction in the rate of cardiac
vents in patients with LQT1 and LQT2 mutations, but no
vident reduction in those with LQT3 mutations (52).
ore recent analyses from the International LQTS Registry
ave attempted to adjust for the fact that in an observational
ohort, beta-blockers are given at the discretion of each
ubject’s attending physician to those considered to be at
igh risk by assessing the benefit of time-dependent beta-
locker therapy in pre-defined risk subsets for each age
roup (28,29,33). The results of these studies have consis-
ently demonstrated that beta-blocker therapy is associated
ith a significant and pronounced reduction in the risk of
ife-threatening cardiac events in high-risk LQTS patients
Table 3). However, despite these beneficial effects, a high
ate of residual cardiac events has been reported in patients
eceiving beta-blocker therapy (28,29,33,52,54). Priori et al.
54) recently showed that, in a cohort of 335 genotyped
QTS patients receiving beta-blocker therapy, cardiac
vents occurred in 10%, 23%, and 32% of LQT1, LQT2,
nd LQT3 patients, respectively. Therefore, patients who
emain symptomatic despite treatment with beta-blockers
hould be considered for other, more invasive, therapies.
mplantable cardioverter-defibrillator (ICD). Implanta-
ion of an ICD was shown to be highly effective in high-risk
QTS patients (55,56). In a study of 125 LQTS patients with
CDs (55), there was 1 death (1.3%) in 73 high-risk ICD
atients, compared with 26 deaths (16%) in 161 non-ICD
atients during mean 8-year follow-up (p  0.07). Further
TS Patients
ecific risk subsets by age group are detailed in Table 3. Kaplan-Meier (K-M)
uscitation; TdP  torsades de pointes; other abbreviations as in Figure 2.in LQ
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Long QT Syndrome June 17, 2008:2291–300nalysis of these data demonstrated a 4% annual rate of ICD
hocks in this high-risk subset (57). Implanted defibrillators in
ombination with beta-blockers are indicated for secondary
revention in LQTS patients and for primary prevention in
igh-risk patients who remain symptomatic despite beta-
locker therapy. Early therapy with an ICD should also be
onsidered in high-risk Jervell and Lange-Nielsen patients,
ecause the efficacy of beta-blocker therapy was found to be
imited in this population (58,59). Recent studies indicate that
family history of premature SCD is not an independent risk
actor for subsequent lethal events in an affected individual
28,29,33,60). Thus, the risk to the remaining family members
s dependent on the surviving family members’ risk factors
QTc duration, history of syncope, gender, and age). Accord-
ngly, our recommendation is that ICD therapy is indicated
nly in high-risk surviving members.
We recently developed a computer-based analytic model
o compare non-ICD with ICD therapy in LQTS patients
age range 10 to 75 years) and showed that primary ICD
herapy is cost-effective in high-risk LQTS males (incre-
ental cost-effectiveness ratio [ICER] $3,328 per quality-
djusted life-year saved.) and cost-saving in high-risk
QTS females (ICER $7,102 gained per quality-adjusted
ife-year saved) (61). This is in contrast to adult patients
ith high-risk acquired cardiac disease, in whom an ICER
n the range of $30,000 to $185,000 per quality-adjusted
ife-year saved was reported (62,63).
urgical left cervicothoracic sympathetic denervation. This
urgical procedure was introduced for the treatment of
QTS before beta-blockers became available (4). LCSD
hould be considered in patients with recurrent syncope
espite beta-blocker therapy and in patients who experience
rrhythmia storms with an ICD. A recent study comprising
47 LQTS high-risk patients showed that after LCSD, 46%
emained asymptomatic. Furthermore, the mean yearly num-
er of LQTS-related cardiac events per patient declined by
1% (p  0.001), and in 5 patients with preoperative ICDs
nd multiple discharges the post-LCSD count of shocks
ecreased by 95% (p  0.02). However, cardiac events,
ncluding SCD, after LCSD occurred in 54% of the study
opulation during long-term follow-up, suggesting a relatively
igh rate of residual risk in treated patients (64).
ther therapeutic considerations. Pacemakers have been
sed in selected LQTS patients with sinus bradycardia, but
ong-term follow-up studies indicate an inappropriately high
ate of SCD in this group of patients (65). A recent report
oints to focal radiofrequency ablation as a potentially valuable
ool in controlling arrhythmogenesis by focal ablation of the
entricular premature beats that trigger tachycardia/fibrillation
n LQTS patients (66). Further experience with this type of
herapy is needed. Gene-specific LQTS therapies, including
odium-channel blockers, potassium-channel activators, alpha-
drenergic receptor blockers, protein-kinase inhibitors, and
tropine, appear to be promising additions to the standard
herapy for LQTS (67). However, current experience with
hese drugs is limited. Preventive measures are important in
1QTS, and adrenergic-type stimuli, alarm clocks, and QT-
rolonging drugs should be avoided.
onclusions and Future Directions
nvestigations of clinical aspects and basic causal mechanisms
f LQTS have provided novel and important insight into the
undamental nature of the electrical activity of the human heart
nd to the relationship between disturbances in ion flow and
ardiac disease. In the past few years, accumulating data from
he International LQTS Registry have facilitated a compre-
ensive analysis of risk factors for life-threatening cardiac
vents, using syncopal history as a time-dependent risk factor
ather than a predominant component of the cardiac event end
oint. Emerging data from these studies have indicated that
he phenotypic expression of this genetic disorder is time
ependent and age specific, displaying important gender dif-
erences in the risk among different age groups. Recent,
ngoing, and cooperative studies from the U.S., Japan, and the
etherlands LQTS registries are providing important
enotype-phenotype information regarding the association be-
ween the biophysical function, type, and location of the
on-channel mutation and outcome in each of the 3 major
QTS genotypes. This information is likely to provide im-
roved criteria for risk assessment in affected patients and the
ackground for innovative therapeutic strategies involving
utation-specific medications and possibly gene therapy.
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